different kidney diseases being targeted so got to be cautious about comparing , but this asset (68% proteinurya reduction against placebo which is huge!) and the Novartis news yesterday that Fabhalta got fda accelerated approval for Iga nepropathy, 38% reduction proteinuria vs placebo just serves to highlight imo the relatively small effect of the dimx asset as a protein in urine reducer (17% vs placebo in phase 2).
Banter and general comments, page-25
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
-0.005(1.20%) |
Mkt cap ! $233.9M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 44.0¢ | 40.5¢ | $671.4K | 1.608M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 134191 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 32384 | 4 |
View Market Depth
| Last trade - 11.51am 16/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |